Mankind Pharma Approves Audited Financial Results for FY26
Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. They also approved the realignment of security cover for existing NCDs post redemption of ₹1,250 Crores, re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for another 5 years, and re-appointed M/s. M. K. Kulshrestha & Associates as Cost Auditors for FY 2026-27. The board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective May 31, 2026, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited. Executive Directors decided not to draw commission for FY 2025-26 to strengthen the company's cash position.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- Security cover realigned for NCDs after ₹1,250 Cr redemption.
- Satish Kumar Sharma re-appointed as Whole-Time Director for 5 years.
- Pramod Gokhale resigned as Global Chief Information Officer, effective May 31, 2026.
- Additional investment of up to ₹500 crores approved for Mankind Medicare Private Limited.
Price Impact
More from MANKIND